29Mar

Idris Oncology one of first companies to receive free human tissue through Codex4SME’s

CURAM3

The Leiden based biotechnology firm Idris Oncology is one of the three SME’s in Europe to receive human tissue through the Codex4SME’s consortium, in order to help them progress their diagnostic product towards clinical application. Interreg project Codex4SME's supports entrepreneurs in Life Sciences & Health sector in obtaining human tissue from biobanks. The application process for tissue can be very lingering and complicated.

The Leiden based biotechnology firm Idris Oncology is one of the three SME’s in Europe to receive human tissue through the Codex4SME’s consortium, in order to help them progress their diagnostic product towards clinical application.

Read our story on the transition to personalized medicine here! (in Dutch)

“It is always hard for SME’s to obtain human samples of any kind,” says Idris CEO and founder Hans Peter Mulder. “That’s why we are so happy with the support from Codex4SME’s and its regional partner InnovationQuarter. What has really speeded Idris’ product development is the fact that Codex4SME’s also covers the costs and assists with the supply form BioBank Graz. This way we can treat cancer better.”

“I’m very happy that Idris was one of the first to obtain these free samples* as it will help making cancer treatment to become more personalized,” says Stéfan Ellenbroek, senior business developer Life Sciences and Health at InnovationQuarter. “There are currently a couple of other Zuid-Holland companies in discussion with the BioBank Graz for prospective tissue collection, but I also urge the rest of the ecosystem to check out this nice chance as the vouchers for free samples are limited in amount. Any companies with questions can contact me!”

Related

EKF expands geographical reach of PCT test for early sepsis detection

Cardiff, UK – 2nd May 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces t...

Read More >

OGT further expands global direct sales and support into Asia-Pacific region

Following successful European rollout, more customers to benefit from enhanced local sales and suppo...

Read More >

In Brief This Week: VolitionRx, Bio-Techne, Biocept, Meridian Bioscience, and More

NEW YORK (360Dx) – VolitionRx reported a second quarter net loss of $3.5 million, or $.13 per share...

Read More >

NEW TEST COULD REVOLUTIONISE THE DIAGNOSIS OF ‘SUPERBUGS’

A new exhibition at the Science Museum, London will feature an invention from the Oxford area which ...

Read More >

On World Cancer Day, Global Good and QuantuMDx Partner to Combat Cervical Cancer

Newcastle upon Tyne, UK – [February 2, 2017] – QuantuMDx Group announced an assay co-development a...

Read More >